日本的面板支持针对帕金森病和心脏病的第一批IPS细胞疗法, Japan's panel backs first iPS cell therapies for Parkinson’s and heart disease, pending minister approval.

日本专家小组建议批准两种用诱导多能干干(IPS)细胞制成的再生药品,如果得到卫生部长的许可,它们有可能成为全球第一种此类药物。 A Japanese expert panel has recommended approval for two regenerative medicines made from induced pluripotent stem (iPS) cells, potentially making them the first of their kind globally if cleared by the health minister. 该疗法针对帕金森氏病和心脏病,规定有条件批准,并持续进行长达7年的安全性和有效性监测。 The therapies, targeting Parkinson’s disease and heart disease, are set for conditional approval with ongoing safety and effectiveness monitoring for up to seven years. 在日本自近20年前发现iPS细胞研究以来的开拓性工作的基础上,这一举动标志着再生医学方面的一个重要里程碑。 This move marks a major milestone in regenerative medicine, building on Japan’s pioneering work in iPS cell research since their discovery nearly two decades ago.